GCLLSG 2016 | Overview of the CLL13 trial: replacing chemotherapy with venetoclax-containing regimens
Julia von Tresckow, MD of University of Cologne, Cologne, Germany, discusses CLL13, a Phase III protocol of the German CLL Study Group aiming to replace chemotherapy with venetoclax-containing regimens (NCT02950051). CLL13 has four arms: standard chemoimmunotherapy as a comparator, venetoclax plus rituximab, venetoclax plus obinutuzumab, and a combination of venetoclax plus ibrutinib plus obinutuzumab. The primary endpoints are: MRD-negativity at 15 months for the comparison of standard chemoimmunotherapy with obinutuzumab plus venetoclax, and progression-free survival (PFS) for the comparison of standard chemoimmunotherapy with a triple combination of venetoclax plus ibrutinib plus obinutuzumab. The CLL13 trial starts in October 2016 in 11 countries. It is a first-line treatment trial designed for fit CLL patients without 17p deletion or TP53 mutation. The objective of the trial is to show that chemotherapy-free regimens are able to show good efficacy and safety and toxicity profile. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
Get great new content delivered to your inboxSign up